title: Confounding by Indication Limits Conclusions of Study of Palivizumab Effectiveness.
authors.affiliation: Pediatric Infectious Diseases, Mayo Clinic boyce.thomas@mayo.edu.
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Boyce
authors.affiliation: Pediatric Infectious Diseases.
authors.forename: Ram
authors.initials: R
authors.lastname: Yogev
authors.affiliation: Pediatric Infectious Diseases.
authors.forename: John P
authors.initials: JP
authors.lastname: DeVincenzo
authors.affiliation: Pediatric Infectious Diseases.
authors.forename: Leonard R
authors.initials: LR
authors.lastname: Krilov
mesh_terms: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D006760:Hospitalization; D006801:Humans; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab